NanoMosaic signed a comarketing agreement with gene therapy developer Solid Biosciences to support manufacturing analytics for AAV gene therapies. The companies will jointly promote NanoMosaic’s Tessie automated plate reader platform alongside Solid’s Polaris-101 capsid technology, combining analytics for vector genomes and capsid characterization with targeted delivery. NanoMosaic said the Tessie platform can measure full, partial and empty capsids as well as transgene and capsid on the same chip—an approach designed to improve clarity on dosing, safety and efficacy. The company noted Tessie received an FDA Advanced Manufacturing Technology (AMT) designation. Solid Biosciences’ Polaris-101 is aimed at skeletal muscle and cardiac tissue delivery, positioning the analytics package as a partner-grade workflow for developers focused on those indications. The collaboration underscores how gene therapy manufacturing is increasingly integrating standardized, high-throughput characterization tools to de-risk clinical translation and regulatory scrutiny.